Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 8Colorectal Neoplasms 6Neoplasm Metastasis 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Thyroid Neoplasms 1Rectal Neoplasms 1Kidney Neoplasms 1Histiocytosis 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Brain Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 24Pemetrexed 18Cisplatin 17Paclitaxel 14pembrolizumab 13Gemcitabine 8osimertinib 7durvalumab 6Docetaxel 6Nivolumab 5Erlotinib Hydrochloride 5130-nm albumin-bound paclitaxel 5capmatinib 3brigatinib 3anlotinib 3Gefitinib 3Drug Therapy 3vosaroxin 2volociximab 2sintilimab 2pralsetinib 2ensartinib 2atezolizumab 2aflibercept 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Panitumumab × Thoracic × Clear all
NCT00034346 2007-12-24

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Amgen

Phase 2 Completed
194 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡